A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.
Phillip M RappoldLynda VuongJosef LeiboldNicholas H ChakiryanMichael CurryFengshen KuoErich SabioHui JiangBriana G NixonMing LiuAnders E BerglundAndrew W SilagyEduardo A MascarenoMahdi GolkaramMahtab MarkerAlbert ReisingAlexander SavchenkoJohn M MillhollandYing-Bei ChenPaul RussoJonathan A ColemanEd ReznikBrandon J ManleyIrina OstrovnayaVladimir MakarovRenzo G DiNataleKyle A BlumXiaoxiao MaDiego ChowellMing O LiDavid B SolitScott W LoweTimothy A ChanRobert J MotzerMartin H VossAbraham Ari HakimiPublished in: Cancer discovery (2022)
Improved understanding of factors that influence metastatic development in localized ccRCC is greatly needed to aid accurate prediction of disease recurrence, clinical decision-making, and future adjuvant clinical trial design. Our analysis implicates intratumoral myeloid inflammation as a key driver of metastasis in patients and a novel immunocompetent mouse model. This article is highlighted in the In This Issue feature, p. 2221.
Keyphrases
- clinical trial
- mouse model
- end stage renal disease
- decision making
- oxidative stress
- bone marrow
- ejection fraction
- dendritic cells
- acute myeloid leukemia
- newly diagnosed
- squamous cell carcinoma
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- free survival
- deep learning
- immune response
- open label
- current status
- study protocol
- phase ii